DexCom Inc (DXCM)vsStryker Corporation (SYK)
DXCM
DexCom Inc
$68.92
+0.37%
HEALTHCARE · Cap: $29.08B
SYK
Stryker Corporation
$305.66
+1.74%
HEALTHCARE · Cap: $119.69B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 425% more annual revenue ($25.27B vs $4.82B). DXCM leads profitability with a 19.3% profit margin vs 13.2%. DXCM appears more attractively valued with a PEG of 1.40. DXCM earns a higher WallStSmart Score of 72/100 (B).
DXCM
Strong Buy72
out of 100
Grade: B
SYK
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.7%
Fair Value
$664.17
Current Price
$68.92
$595.25 discount
Margin of Safety
-37.9%
Fair Value
$223.22
Current Price
$305.66
$82.44 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Earnings expanding 92.2% YoY
Strong operational efficiency at 21.4%
15.0% revenue growth
Large-cap with strong market position
Areas to Watch
Premium valuation, high expectations priced in
Trading at 9.0x book value
Premium valuation, high expectations priced in
2.6% revenue growth
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, EPS Growth, Operating Margin. Profitability is solid with margins at 19.3% and operating margin at 21.4%. Revenue growth of 15.0% demonstrates continued momentum.
Bull Case : SYK
The strongest argument for SYK centers on Market Cap. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Bear Case : SYK
The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
DXCM profiles as a mature stock while SYK is a value play — different risk/reward profiles.
DXCM carries more volatility with a beta of 1.44 — expect wider price swings.
DXCM is growing revenue faster at 15.0% — sustainability is the question.
DXCM generates stronger free cash flow (449M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (72/100 vs 57/100), backed by strong 19.3% margins and 15.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?